VERASTEM, INC.
VSTM US92337C2035
🆔
Registration No.
4853179
💰
Capitalization
Small-cap
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
🔗
Website
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7% | -81% | 62% | -38% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
📊
Transactions
71
🙍
Insiders
5
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Calkins Daniel CFO |
9.23 USD |
25 Sold |
231 USD |
22/09/2025 | 24/09/2025 |
| Calkins Daniel CFO |
9.08 USD |
57 Sold |
518 USD |
22/09/2025 | 22/09/2025 |
| Paterson Dan CEO |
9.99 USD |
390 Sold |
3,896 USD |
16/09/2025 | 16/09/2025 |
| Stuglik Brian M O |
9.99 USD |
587 Sold |
5,864 USD |
16/09/2025 | 16/09/2025 |
| Gagnon Robert E. O |
9.99 USD |
281 Sold |
2,807 USD |
16/09/2025 | 16/09/2025 |
| Paterson Dan CEO |
5.81 USD |
1,332 Sold |
7,739 USD |
06/08/2025 | 06/08/2025 |
| Calkins Daniel CFO |
4.71 USD |
25 Sold |
118 USD |
20/06/2025 | 23/06/2025 |
| Calkins Daniel CFO |
5.13 USD |
4,110 Sold |
21,084 USD |
20/06/2025 | 20/06/2025 |
| Paterson Dan CEO |
5.13 USD |
17,808 Sold |
91,355 USD |
20/06/2025 | 20/06/2025 |
| Stuglik Brian M O |
5.65 USD |
594 Sold |
3,356 USD |
16/06/2025 | 16/06/2025 |